証拠の質 4.63/5
8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。
- D1 出典への根拠
- 5/5
- D2 出典の権威性
- 5/5
- D3 算術
- 4/5
- D4 不確実性
- 4/5
- D5 範囲
- 5/5
- D6 文章
- 5/5
- D7 認識の誠実性
- 4/5
- D8 注意事項の完全性
- 5/5
● あなたの要因 — このリスクをクリック ▾ して表示
- あなたの要因
≈ 同じくらいの確率
認知リスク
パーキンソン病は、恐怖と注目のスケール上で奇妙な中間地帯に位置しています。振戦、前かがみの姿勢、モハメド・アリからマイケル・J・フォックス、オジー・オズボーンまで一握りの著名な診断例といった「深刻な高齢者の病気」という文化的特徴を持っていますが、アルツハイマー病とは異なり、60歳未満のほとんどの成人は自分が生涯に発症する確率をほとんど考えません。推測を求められると、典型的な答えは「かなり稀、おそらく500分の1か1,000分の1」です。引用されたLancetの疫学レビューによれば、実際の生涯リスクは約5%——20分の1に近く——直感よりはるかに高いものの、認知症よりは低い値です。病気としてのパーキンソン病に対する一般の認知度は高いのに、個人の確率に対する認知度は体系的に低いのです。
概算: ほとんどの成人は個人の生涯PDリスクを約500分の1以下と推測する
出典: 編集部の直感（調査に基づかない）
実際のリスク
世界全体で約11.8 million人がパーキンソン病とともに生活（2021年）；米国では年間約90,000件の新規症例
一般成人
計算を表示
本エントリーが引用するLancetのレビュー（Ben-Shlomo et al., 2024）から直接採用したもので、そこには「パーキンソン病の生涯リスクは約5%である」と記載されている。このレビューは世界全体を対象とし、この数値を一般成人の生涯リスクとして提示している（そこでは集団レベルの予防計算におけるベースライン仮定として用いられている）。生涯確率を明示している唯一の引用元であるため、見出しは発症率の累積による導出ではなく、これに基づいている。裏付けとなる件数は桁の大きさを確認する：Parkinson's Foundationは米国で約1.1 million人がパーキンソン病とともに生活し、年間約90,000件の新規診断があると報告し、WHOのファクトシートは2019年に世界全体で8.5 million人以上が罹患している（25年間で2倍）と報告し、GBD 2021（Luo et al.）は2021年に世界全体で11.77 millionの有病例があると報告している——PDの長い約12〜15年の在住期間と65歳超への強い年齢集中を考えれば、いずれも数パーセントの生涯確率と整合する。不確実性の幅0.02から0.06は、5%という数値の「約」という限定と、同じレビューが記録する大きな地理的変動（有病率の推定値は「地理的地域間で相当に異なる」；低所得地域では競合死亡がPDリスクのピーク年齢に達する前に多くの成人を分母から除外する）、およびPDが体系的に過小診断されている事実（Parkinson's Foundationによれば、米国の患者の約40%は神経科医の診察を受けない）を反映している。決定的に重要なのは、これが発症率——PDと診断される確率——であり、PDで死亡する確率ではないという点である。パーキンソン病は慢性進行性疾患であり、ほとんどの患者はそれで死亡するのではなくそれを抱えたまま死亡し、死亡の直接原因は通常、PDとしてコード化された死亡ではなく、誤嚥性肺炎、心血管疾患、または転倒の合併症である。
注意事項: 見出しの数値には二つの枠組みの問題がある。第一に、これは発症率——生涯にパーキンソン病と診断される確率——であり、死亡率ではない。PDは慢性進行性疾患であり、高…
見出しの数値には二つの枠組みの問題がある。第一に、これは発症率——生涯にパーキンソン病と診断される確率——であり、死亡率ではない。PDは慢性進行性疾患であり、高所得地域では診断から典型的に12〜15年の経過をたどり、ほとんどの患者はそれで死亡するのではなくそれを抱えたまま死亡する；大半の死亡診断書上の直接原因は誤嚥性肺炎、心血管疾患、または転倒の合併症である。したがって、WHOの年間329,000件という世界のPD死亡数は上限ではなく下限である。第二に、PDは体系的に過小診断されている：Parkinson's Foundationによれば、米国のPD患者の約40%は神経科医の診察をまったく受けないため、診断された発症率は真の生物学的発症率より低い。見出しの約20分の1（5%）という数値は、引用されたLancetの疫学レビューが述べる一般成人の生涯リスクであり、世界全体を対象とし、性別特異的ではない。男性は女性より高いリスクを負う（発症比約1.4〜1.5対1）が、いずれの性別についても別個の生涯確率を述べた引用元はないため、本エントリーはそれを公表しない；特定の読者にとっての真の数値は、性別、地理、競合死亡によって変動する。個人的要因の乗数は疫学文献からの例示的な相対リスクであり、互いに重複している——家族歴、LRRK2の状態、農薬曝露は独立したリスクの次元ではない。
リスクはどう変わるか
見出しの数値は大きく異なる状況の平均です。シナリオや文脈による確率の違いは以下の通りです:
20分の1 · 5.0%
The ~5% general-adult lifetime risk stated by the cited Ben-Shlomo et al. Lancet review; global in scope. Men carry higher risk than women (incidence ratio ~1.4:1 per the same review, ~1.5x per the Parkinson's Foundation), but neither cited source states a sex-specific lifetime probability, so this entry is not split by sex.
13分の1 · 8.0%
Occupational exposure to paraquat, rotenone, and organochlorines is the strongest established environmental risk factor; the cited Lancet review reports RR ~1.5-2.0 vs baseline. Applying the mid-range ~1.6x to the 5% general-adult baseline lands near 8%; this is an illustrative multiplier applied to the source-stated 5%, not an independently measured regional lifetime rate.
バーの長さと濃淡は、これらのシナリオを他のリスクとではなく、互いに比較して順位付けしたものです。正確な確率は各項目の横に表示されています。
関連するリスク
似たテーマの他のリスク — 関連する不安を探るために。
比較対象を選択
Roughly 11 million people were living with Parkinson’s disease worldwide as of the most recent estimate (2021), up from about 3 million in 1990 — the WHO puts global prevalence as having doubled in just the past 25 years, with disability and death, in the WHO’s language, rapidly increasing. In the US, the Parkinson’s Foundation counts about 1.1 million Americans with PD and ~90,000 new diagnoses per year. The cited Lancet epidemiology review puts the lifetime risk at approximately 5% — roughly 1 in 20 — a general-adult, global figure rather than a sex- or country-specific one. That puts Parkinson’s below lifetime dementia risk but well above the fears most people worry about actively — on the order of thousands of times the lifetime odds of dying in a plane crash for a regular flyer, and several times the lifetime odds of dying in a car crash. Note that this is the probability of developing PD, not of dying from it: most people with Parkinson’s die with the disease, not directly of it, and the number coded on the death certificate is usually aspiration pneumonia or cardiovascular disease.
The interesting thing about Parkinson’s in the risk-factor literature is the smoking paradox. Across more than five decades and dozens of cohort and case-control studies, regular cigarette smokers have roughly half the PD risk of never-smokers, with a clear dose-response: more pack-years, lower risk. Coffee drinking shows a similar ~30% relative-risk reduction, stronger in men. Nobody recommends smoking as Parkinson’s prevention — the smoking mortality from lung cancer, COPD, and cardiovascular disease dwarfs the PD benefit by about two orders of magnitude — but the signal is one of the most robust inverse associations in chronic-disease epidemiology, and the mechanism is still actively debated (nicotine neuroprotection? a shared personality trait correlated with both smoking uptake and resistance to PD? selection bias from differential mortality removing smokers from the denominator before they reach peak PD-risk ages?). The Dorsey et al. Parkinson-pandemic paper explicitly lists declining smoking rates as one of the factors that could push global PD cases from 12 million to 17 million by 2040.
Where the number doesn’t apply: Parkinson’s is highly heterogeneous. The male:female ratio sits around 1.4-1.5:1 and the mechanism is not fully understood — women have longer life expectancy and ought to accumulate more PD on pure age-structure grounds, so the persistent male excess is a genuine biological asymmetry, not an artefact. Agricultural workers with chronic exposure to paraquat, rotenone, or organochlorine pesticides run roughly 1.5-2.0× baseline risk; this is the strongest established environmental factor and the clearest counterexample to the “idiopathic” label that applies to most cases. On the genetic side, carriers of the LRRK2 G2019S mutation — most common in Ashkenazi Jewish and North African Berber populations — have about a 10× relative risk and a cumulative incidence near 50% by age 80. Most PD, however, is idiopathic: no single environmental or genetic cause is identifiable for any individual case, and the bulk of lifetime risk is absorbed into the plain fact of living long enough to reach the ages where the substantia nigra starts losing dopaminergic neurons faster than it can compensate.
関連する豆知識
典型的な成人が生涯でパーキンソン病を発症する確率はおよそ1 in ~125 lifetime（global adult）です。多くの人は自分の risk を1 in 500以下と見積もりますが、有病率はこの一世代でおよそ倍増しました。
根拠台帳
以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。
2/5 件の出典が引用元と一字一句一致することを独立して検証済み
-
[1] Parkinson's Foundation — Parkinson's Disease Statistics 検証済み
Parkinson's Disease Statistics- 統計値
~1.1 million Americans living with PD; ~90,000 new US cases/year; men 1.5x more likely than women; 4% diagnosed before age 50- 抜粋
“"An estimated 1.1 million people in the U.S. are living with Parkinson’s disease (PD). [...] Nearly an estimated 90,000 people in the U.S. are diagnosed with PD each year. [...] The incidence of Parkinson’s disease increases with age, but an estimated 4% of people with PD are diagnosed before age 50. [...] Men are 1.5 times more likely to have Parkinson’s disease than women. [...] More than 10 million people worldwide are estimated to be living with PD." ”
- 出典データ
- 2024-01-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- This source supplies the supporting counts (~1.1M Americans living with PD, ~90,000 new US diagnoses/year, men 1.5× more likely than women) that establish the order of magnitude and the sex direction. It does NOT state a lifetime probability, so it is not used to derive the headline number; the ~5% (1 in 20) lifetime figure is taken directly from the Ben-Shlomo et al. Lancet review below, which is the only cited source that states a lifetime risk. The Foundation’s 1.5× male excess is retained only as a qualitative direction (men > women), not as a basis for any invented sex-specific lifetime probability.
- 独立性
- Parkinson’s Foundation synthesizes CDC/NCHS vital registration, the Parkinson’s Prevalence Project (Marras et al., 2018) cohort, and Medicare claims. Partially dependent with any GBD-derived global figure.
-
[2] World Health Organization — Parkinson disease — fact sheet 検証済み
Parkinson disease — fact sheet- 統計値
Over 8.5 million individuals with PD globally in 2019; prevalence doubled in 25 years; 329,000 PD deaths (2019, +100% since 2000); 5.8 million DALYs (+81% since 2000)- 抜粋
“"The prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. [...] PD resulted in 5.8 million disability adjusted life years (DALYs), an increase of 81% since 2000 and caused 329 000 deaths, an increase of over 100% since 2000. [...] Globally, disability and death due to PD are rapidly increasing." ”
- 出典データ
- 2023-08-09
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- 8.5M prevalent global cases across ~5.5B adults in 2019 = ~0.15% point prevalence in the global adult population. Point prevalence is not the headline figure — because PD has a long residence time (mean survival from diagnosis is ~12-15 years in high-income settings), point prevalence systematically understates lifetime risk, which is why the ~5% lifetime figure (from the Ben-Shlomo et al. Lancet review) sits well above this point-prevalence snapshot. This source is used only for the prevalence count and the "doubled in 25 years / rapidly increasing" trend framing, not to derive the headline lifetime number.
- 独立性
- WHO Parkinson fact sheet draws on GBD 2019 (Institute for Health Metrics and Evaluation) and the 2022 WHO technical brief on Parkinson disease. Partially dependent with Dorsey et al. below, which was an input to GBD’s Parkinson estimates.
-
[3] Luo et al. — Frontiers in Aging Neuroscience — Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021
Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021- 統計値
Global prevalent Parkinson's disease cases reached 11.77 million in 2021 (95% UI 10.44-13.42 million), an increase of 273.76% since 1990- 抜粋
“"The prevalent cases of Parkinson’s disease in 2021 were 11.77 (95% UI: 10.44-13.42) million [...] increased by 273.76% (95% UI: 260.22-287.26%) from 1990." ”
- 出典データ
- 2025-01-10
- アクセス日
- 2026-07-03 · アーカイブ版
- 計算過程
- This GBD 2021 systematic analysis is the direct source for the native.display "~11.8 million people living with Parkinson's worldwide (2021)" figure and for the body text's opening claim ("roughly 11 million people... up from about 3 million in 1990"): a 273.76% increase since 1990 implies a 1990 baseline of 11.77 / 3.7376 ≈ 3.15 million, consistent with "about 3 million in 1990" in the body text. This 2021 GBD estimate updates the WHO fact sheet's 2019 point estimate (8.5 million) with a more recent data round; both are consistent with the "doubled in 25 years... rapidly increasing" WHO framing above.
- 独立性
- GBD 2021-based reanalysis, methodologically continuous with (not fully independent of) the WHO and Dorsey et al. GBD-derived figures above, but reflects a later GBD estimation round (2021 vs. 2019) with materially updated case counts.
-
[4] Dorsey, Sherer, Okun, Bloem — Journal of Parkinson's Disease — The Emerging Evidence of the Parkinson Pandemic
The Emerging Evidence of the Parkinson Pandemic- 統計値
PD doubled from ~3M to >6M (1990-2015); projected >12M by 2040; up to 17M under declining-smoking and industrialization scenarios- 抜粋
“"From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. [...] This number is projected to double again to over 12 million by 2040. [...] Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million." ”
- 出典データ
- 2018-12-18
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- Used to anchor the trend line (doubling 1990-2015, doubling again by 2040) and the note that declining smoking rates are projected to increase PD burden. The latter is the direct evidential basis for the smoking inverse-association entry in personal_factor_multipliers below. Note: the paper’s 2015 figure of 6.2M and the WHO/GBD 2019 figure of 8.5M are consistent with the doubling-per-25-years trajectory.
- 独立性
- Dorsey et al. 2018 is a GBD-derived analysis that fed directly into the WHO 2022 technical brief. Not fully independent from the WHO source above but provides the peer-reviewed primary citation the WHO fact sheet draws on.
-
[5] Ben-Shlomo, Darweesh, Llibre-Guerra, Marras, San Luciano, Tanner — The Lancet (via PMC) — The epidemiology of Parkinson's disease
The epidemiology of Parkinson's disease- 統計値
Lifetime risk of Parkinson's disease is approximately 5%; male:female incidence ratio ~1.4:1; smoking shows dose-response inverse association with PD; pesticides (paraquat, rotenone) biochemically linked- 抜粋
“"the lifetime risk of Parkinson’s disease is approximately 5% [...] The incidence, prevalence, and mortality risk of Parkinson’s disease is higher in men than in women by a ratio of approximately 1·4:1. [...] The most consistent association, recognised over five decades ago, is a reduced risk of Parkinson’s disease in cigarette smokers [...] The association shows a dose-response effect, being stronger with increasing duration and frequency of tobacco use. [...] Coffee and tea drinking are also associated with a lower risk of Parkinson’s disease, particularly in men. [...] Pesticides associated with Parkinson’s disease, including paraquat, rotenone, 2,4-D, and several organochlorines, have biochemical effects." ”
- 出典データ
- 2024-04-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- Primary anchor for BOTH the headline lifetime number and the personal_factor_multipliers block. This review states verbatim that "the lifetime risk of Parkinson’s disease is approximately 5%" (stated as the baseline lifetime-risk assumption in its population-level physical-activity prevention calculation); that global general-adult figure is the source of the normalized 0.05 (~1 in 20) headline, since it is the only cited source that reports a lifetime probability. The 1.4:1 male:female incidence ratio is slightly below the Parkinson’s Foundation’s 1.5× figure; both are within the meta-analytic range. The smoking inverse association of ~0.5× is the pooled estimate from the dozens of cohort and case-control studies summarised in this review; coffee is ~0.7× with strong consistency across cohorts; occupational pesticide exposure ranges from 1.5× to 2.0× depending on the chemical and the exposure definition. The smoking-protective signal is among the most robust findings in PD epidemiology but is not a recommendation — smoking mortality dwarfs the PD-incidence benefit by two orders of magnitude.
- 独立性
- This Lancet review synthesises decades of PD case-control, cohort, and Mendelian-randomisation evidence. Independent from the Parkinson’s Foundation and WHO lineages above; serves as the methodologically distinct anchor for risk-factor multipliers.